Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA
Enzo Batistella1, Laia Paré2, Mihir Sahasrabudhe1, Tomás Pascual2, Maria Vakalopoulou3, Patricia Villagrasa2, Eric Deutsch4, Núria Chic5, Guillermo Villacampa6, Paolo Nuciforo7, Javier Cortes8, Antonio Llombart-Cussac9, Nikos Paragios10 and Aleix Prat5
Communication in congress
ePoster
SABCS
2020
